Unchained Labs | Life Sciences Tools

Vision

Build the first Biologics tools pure play.

Path

Acquire right. Invest like crazy. Create something UNbelievable.

People

The right group of people can accomplish anything.

Products

Biologics are a pain. That’s why we uncaged the right tools for the job. Ones that make a big-time difference in figuring them out. Products that characterize even the most unruly molecules and totally crank up your research.

Events

CONFERENCES & WORKSHOPS

PEGS Boston

Apr 30 - May 4, Boston, MA. Booth 407. Register.

Formulation & Drug Delivery UK Congress

May 8-9, London, UK. Register.

Isber

May 20-24, Dallas, TX. Booth 306. Register.

The Bioprocessing Summit

Aug 13-16, Boston, MA. Booth 307. Register.

BioProcess International

Sep 4-7, Boston, MA. Register.

8th American DDF Summit

Sep 10-11, San Francisco, CA. Register.

PEGS Europe

Nov 13-17, Lisbon, Portugal. Booth 210. Register.

PAST WEBINARS

CHI Webinar: Hit the stability jackpot with Hunky: Quantify protein stability and assess aggregation risks

Feb 28, 2018 Watch recording.

CHI Webinar: Cruise through more with Lunatic: Batch-wise quantification of biologics even at the highest concentrations

Feb 22, 2018 Watch recording.

Tech Networks Webinar: See stability in hi-def with Hunky

Nov 2, 2017 Watch recording.

Introducing LEA 9: Design workflows easier than ever before!

Oct 10, 2017 Watch recording.

CHI Webinar: Up Your Game in Protein Quantification with Lunatic - Higher Throughput and Concentrations

Sep 28, 2017 Watch recording.

Rip through formulation prep with Grunt and Junior

Sep 7, 2017 Watch recording.

News

Apr 16, 2018

Unchained Labs crushes it with Uncle 3.0! Read more.

Unchained Labs crushes it with Uncle 3.0!

April 16, 2018 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, released its Uncle 3.0 software today. This update adds a brand-spanking new application and makes Uncle QC-ready for biologics labs.

When formulating proteins at high concentrations, G₂₂ measurements are the only way for scientists to quickly tell if a formulation makes their protein more apt to stick to itself or not. Uncle is the first platform to give researchers a G₂₂ for their biologic with just a click of a button, letting them check for attractive forces that could cause aggregation troubles later on.

For scientists working in regulated environments, where controlling access to data and keeping its integrity are a must-have, the new 21 CFR Part 11-compliant software tools in Uncle 3.0 software can be turned on without a hitch.

“Uncle’s still the go-to instrument for screening protein stability. With the 3.0 release, high-concentration biologics can be assessed earlier in development. That’s a huge deal because these formulations are more effective and can be dosed less often, but are also at higher risk for aggregation,” said Taegen Clary, VP of Marketing at Unchained Labs. “The new compliance features we’ve added to our Uncle also make it a piece of cake for customers to transfer their applications to QC.”

About Unchained Labs

Here’s the deal. We’re all about helping biologics researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
VP of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Mar 27, 2018

Unchained Labs keeps them coming, acquires rap.ID! Read more.

Unchained Labs keeps them coming, acquires rap.ID!

March 27, 2018 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, acquired rap.ID today. Rap.ID is a leading provider of systems used for particle identification in biopharmaceutical development and quality control. The company also provides contract services in these areas. This is Unchained Labs’ 6^th acquisition in just over 3 years.

Particles muck up the quality of a drug and can shut down its production. Single Particle Explorer is the only tool out there that identifies particles by their shape and then forensically identifies them by their chemical and elemental fingerprints. In minutes, researchers know the culprit without a doubt, can track it back to the source, and fix their workflow or manufacturing process.

Silicone oil makes it easier to dispense drugs from injectable devices. Layer Explorer lets researchers measure the thickness and consistency of the silicone, so they can fine-tune their processes to use only a thin, uniform layer to minimize the amount that gets into their formulation.

“These products are great additions to our biologics tools arsenal. We can now help our customers identify the source of any particle that shows up in their process,” said Tim Harkness, Founder and CEO of Unchained Labs. “This acquisition expands our portfolio firmly downstream into biologic quality control.”

“Unchained Labs is an ideal home for our products and employees,” said Dr. Oliver Valet, Managing Director of rap.ID. “They have a great platform to help realize the potential for our products.”

In just over 3 years, Unchained Labs has grown to over 180 employees, $50M+ in revenue, 9 product lines and has direct distribution around the world. In connection with this transaction, the company raised $17M in a Series D financing. Novo Ventures, Canaan Partners, TPG Biotech and Tri-Valley Ventures all participated in the financing.

About Unchained Labs

Here’s the deal. We’re all about helping biologics researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
VP of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Jan 8, 2018

Unchained Labs gives Lunatic a boost, nails high-end biologic quant! Read more.

Unchained Labs gives Lunatic a boost, nails high-end biologic quant!

January 8, 2018 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, amped up the protein quant range on Lunatic today, making measurements of up to 250 mg/mL IgG a cinch for biologics researchers.

High-concentration biologics don’t have to be administered as often, plus patients see better results. Lunatic’s new IgG Quant app hits the upper analysis range needed to measure these protein drugs, and does it with only 2 µL of sample straight up – no dilution needed.

Lunatic is the go-to, high-throughput tool for measuring biologic concentrations – from early research to QC. Other tools are kluge, run only a handful of samples at a time, require sample dilution which can skew results, or use way too much sample for early-stage analysis.

“What makes Lunatic special is that it can now reach the protein quant range scientists are really looking for,” said Taegen Clary, VP of Marketing at Unchained Labs. “Because Lunatic uses super small volumes, it can be used upstream when there’s boatloads of samples but not much of them to work with and downstream when there’s buckets of only a few that need analysis. So it’s the ideal tool for measuring protein concentration at all stages of biologics development.”

About Unchained Labs

Here’s the deal. We’re all about helping biologics researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
VP of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Nov 7, 2017

Unchained Labs drifts into Tokyo, opens new office in Japan Read more.

Unchained Labs drifts into Tokyo, opens new office in Japan

November 7, 2017 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, announced the opening of its new office in Japan and new London location today. The new Tokyo office, right in the heart of the city, is Unchained Labs’ 6^th office worldwide.

Unchained Labs is headquartered in Pleasanton, California, near Silicon Valley, and has offices and applications labs in Boston, London, Brussels, and Shanghai.

The new Tokyo office will be the home for sales and scientific staff, and has an applications lab ready to go for product demos. Also, today, the company has opened its new London location, right across the street from Heathrow Airport. This new office will be used for product development activities and product demos for customers.

“The biologics market is growing like crazy all over the world,” said Tim Harkness, Founder and CEO of Unchained Labs. “The Japanese market is no exception and now’s the time to kick our operations there into gear.”

About Unchained Labs

Here’s the deal. We’re all about helping biologics researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
VP of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Oct 24, 2017

Unchained Labs bulks up the Board, adds Max Carnecchia Read more.

Unchained Labs bulks up the Board, adds Max Carnecchia

October 24, 2017 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, announced the appointment of Max Carnecchia to its Board today.

Max is currently the Chief Executive Officer of Illuminate Education, which creates cloud delivered tools for educators that promote student success. Over 7 million K-12 students benefit from the Illuminate Education solutions.

Prior to Illuminate Education, Max was the Chief Executive Officer of BIOVIA-Dassault Systèmes and before that the President and CEO of Accelrys, which Dassault Systèmes acquired in 2014. Max led Accelrys through significant growth and transformation, successfully transitioning the company into the leading global provider of scientific product lifecycle management software and services.

“I am absolutely thrilled to have Max join our Board,” said Tim Harkness, Founder and CEO of Unchained Labs. “Max’s experience running the world’s largest life sciences software company brings a unique perspective to the table.”

About Unchained Labs

Here’s the deal. We’re all about helping biologics researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
VP of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Oct 10, 2017

Unchained Labs brings biologic stability into hi-def, launches Hunky! Read more.

Unchained Labs brings biologic stability into hi-def, launches Hunky!

October 10, 2017 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, launched Hunky today, the one and only complete solution for quantifying biologic stability and predicting aggregation.

Hunky measures ΔG, the amount of energy it takes to unfold a protein, letting scientists quantify exactly how much denatured protein they’ve got in their samples. Its hands-off workflow and automated data analysis lets scientists see even small differences in their protein’s stability.

Aggregation is bad news that usually shows up after it’s too late. Hunky solves this by measuring ΔG at high and low protein concentrations to predict whether a protein aggregates from the native or denatured state. Scientists will know they have an aggregation problem right away and get insight on what they should do next.

“With Hunky, scientists get the scoop on how stable their proteins are, whether they aggregate, and what pathway they’ll take,” said Taegen Clary, VP of Marketing at Unchained Labs. “They can stop stressing out for months, waiting to find out if they’ve made the right decisions.”

About Unchained Labs

Here’s the deal. We’re all about helping biologics researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
VP of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Sep 19, 2017

Unchained Labs makes automation workflows a cinch, releases LEA 9! Read more.

Unchained Labs makes automation workflows a cinch, releases LEA 9!

September 19, 2017 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, released its LEA 9 software today, making Freeslate and Junior automation systems way more accessible.

LEA, short for Laboratory Execution and Analysis Software, controls Freeslate and Junior systems, executes biologics and chemistry workflow designs, integrates third-party tools, and keeps all the data in one place.

LEA 9 adds a step-by-step workflow tool called Design Creator into the mix. There’s no coding, scripting or messing around with protocols. Scientists just drag and drop their workflow steps into place and they’re good to go. Design Creator also double checks each step to make sure it’s doable, so newbie users don’t have to worry about screwing things up.

“Freeslate and Junior already help researchers wipe out major hassles from their toughest workflows,” said Taegen Clary, VP of Marketing at Unchained Labs. “Automation can be insanely complicated, and really nerve wracking for casual users. LEA 9 makes lab automation totally easy and approachable for anyone.”

About Unchained Labs

Here’s the deal. We’re all about helping biologics researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
VP of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Aug 21, 2017

Unchained Labs gets its quant on, launches Lunatic! Read more.

Unchained Labs gets its quant on, launches Lunatic!

August 21, 2017 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, launched Lunatic today at the Bioprocessing Summit conference in Boston. Lunatic, a.k.a. The Concentration Liberator, makes batch quantification of protein, DNA and RNA a reality for biologics and genomics researchers.

Lunatic is the only UV/Vis system out there that can measure biologics in high-throughput and at high concentrations. All it takes is 2 μL and 5 minutes to measure up to 96 samples. For biologics researchers, Lunatic measures up to 150 mg/mL of their monoclonal antibodies, straight up, so they’ll never need to dilute again.

DNA and RNA samples are freaking messy. Lunatic analysis software lets genomics researchers see impurities that classic UV/Vis measurements regularly mistake as their DNA or RNA. They’ll now know if their samples are good to go or if they need another round of cleanup.

“Lunatic puts the kibosh on the annoying and painful parts of measuring concentration,” said Taegen Clary, VP of Marketing at Unchained Labs. “It stops the run one sample, clean, repeat madness, so scientists can crank through more measurements than ever before. All they need to do is load their samples and get killer results.”

About Unchained Labs

Here’s the deal. We’re all about helping biologics researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
VP of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release .

Old News

Need more? Check out news from prior years.

Our Team

READ BIO

Tim Harkness

Founder and CEO

Tim Harkness, Founder and CEO

Building great teams and great life sciences companies is just in Tim’s DNA. He has 2 successful exits under his belt and brings 20+ years of life science leadership experience to the Unchained Labs table. As CEO of ProteinSimple, Tim and team built a unique protein analysis pure-play from scratch and sold it for $300M. Prior to that he helped build Molecular Devices into a diversified life science tools provider and sold it for over $600M. In his early career as a healthcare investment banker, Tim helped raise over $1B for life science companies in the public equity markets. He currently sits on the Board of Directors at Data Sciences International, a private life science technology company and at ALDA, the Life Sciences and Diagnostic Tools Association. He is a Founding Venture Partner at Tri-Valley Ventures, has an M.B.A. from Stanford and a B.B.A from the University of Wisconsin. Tim is married with 3 children, is out hacking around on the links or riding his bike whenever he can, and happily gets up at the crack of dawn to coach his son’s hockey and lacrosse teams.

READ BIO

Jason Novi

CFO and COO

Jason Novi, CFO and COO

Jason wears a bunch of hats and loves to build businesses. He leads the finance, manufacturing, service and administrative functions for Unchained Labs, and is on the front line of fundraising, acquisitions and integrations. Prior to joining Unchained Labs, Jason was the CFO and VP of Operations at ProteinSimple, a part of Tim’s team that raised $60M, acquired four businesses and built a $60M+, profitable life sciences tools company over a six year period. That business was sold to Bio-Techne in July 2014 for $300M. Prior to joining ProteinSimple, Jason was VP of Finance at Nektar Therapeutics. Earlier in his career, he spent nearly seven years in various senior financial leadership roles at Molecular Devices, responsible for the worldwide accounting, finance and treasury functions, and Jason played a key role in the execution and integration of its corporate development activities. He began his career with Ernst & Young, based in San Francisco, California, holds a B.S. in Business Administration from Cal Poly San Luis Obispo, and is a CPA (inactive). Jason and his wife Erin have two kids, and when he isn’t coaching their softball and baseball teams, you can find him hacking away on the golf course or cheering on the SF Giants and 49ers.

READ BIO

Terry Salyer

CCO

Terry Salyer, CCO

Terry is all about helping customers up the pace of their research through better tools, and has sold thousands of life science systems in her 20-year career. Terry leads Global Commercial Operations at Unchained Labs, supporting customers with her field sales and applications teams. Prior to Unchained Labs, Terry was CCO at BioNano Genomics and VP of Sales at ProteinSimple, Pall ForteBio and Eksigent. She helped develop and sell products at each, and was integral in demonstrating the scientific impact of these new technologies to customers. Terry has a B.S. in Biotechnology from Minnesota State at Mankato. She spends her free time cooking and golfing, and jumps at the chance to travel to a great beach location any time she can. Terry is a huge fan of the Minnesota Vikings and plans on watching them take a Super Bowl someday.

READ BIO

Will Lachnit

VP Corporate Dev

Will Lachnit, VP Corporate Dev

Will’s been around the Life Sciences block a time or two, and can’t get enough when it comes to making companies thrive. He has over 25 years of experience in the life sciences industry across multiple functions. Prior to joining Unchained Labs, Will was the Senior Vice President of Global Sales and Solutions Development at Freeslate. Prior to Freeslate, he was the Vice President of Sales and Service for ProteinSimple. While there, his other roles included leadership of the marketing and applications functions and he played a key role in integrating 4 acquisitions. Previously, at Molecular Devices Corporation, Will had leadership roles for the North American Drug Discovery sales organization, an entrepreneurial product development organization in Switzerland, and Corporate Development. Dr. Lachnit started his career in Pharmaceutical R&D in scientific and research management positions at Roche and Syntex, including running a best-in-class HTS organization. He received his M.S. and Ph.D. in Pharmacology and his B.S. in Physiology from the University of California, Davis. Will has a passion for cooking for his family and loves tinkering around in his woodshop.

READ BIO

Krista Witte

VP Product Dev

Krista Witte, VP Product Dev

Krista loves building assays and analytical tools to do great science. She has over 15 years of experience in life sciences instrumentation and application development. Prior to joining Unchained Labs, Krista was a founding team member of ForteBio, now Pall ForteBio. In her decade at the company, she held many roles including heading up Applications, Assay Development, System Integration, QC and R&D. She saw the company from angel-funded start-up to a leading provider of label-free instrumentation. Prior to ForteBio, Krista headed up the Applications team at Zyomyx, taking a lead role in developing their protein microarray technology. Krista holds a Ph.D. in Carbohydrate Chemistry from The Scripps Research Institute and a B.S. in Chemistry from Texas A&M (Gig ‘em Aggies!). When not doing science, Krista is obsessed with being around the water and can be found swimming, diving or sailing.

READ BIO

Taegen Clary

VP Marketing

Taegen Clary, VP Marketing

Taegen loves marketing life science tools. He has over 15 years of experience using and marketing enabling life science instrumentation and consumables. As the Director of Pharmaceutical Segment Marketing at Agilent Technologies, he led the marketing organization focused on the company’s largest customer segment, which has experienced consistent, above-market growth rates and 2014 sales revenues of $1B. Over his 7 years at Agilent, Taegen was the Product Manager for Proteomics and Protein Chemistries and also led the Life Science group’s efforts in the area of protein therapeutics. He began his career at Berlex Biosciences, now a part of Bayer Healthcare, running mass spectrometers and developing assays to measure drug passage across the blood brain barrier. Taegen has an M.B.A. in Marketing from St. Mary’s College of California and a B.S. in Biotechnology from the University of California, Davis. Taegen is married with two children, loves mountain biking, camping, fishing, golfing and is huge fan of the San Francisco Giants and 49ers.

jobs

Unchained people get amazing amounts of work done, focus on what matters and never give up. They thrive on mind-blowing results and make decisions with incomplete information on a daily basis. They’re team players that always know it’s all about we, not I.

We move fast and expect a lot. So if you’re not down with the unknown, making mistakes and feeling accountable, stop reading. But if a fast pace, autonomy, flexibility and real responsibility float your boat, just hit the button and send your resume on in. We’re hiring for the following positions:

Admin

Accountant-Europe

Service

Field Service Engineer-New England

Operations

Materials Manager
Production Technician
Systems Integration Engineer

Sales & Applications

Automation Sales-Japan
Sales Specialist-California
Field Automation Scientist-Europe
Strategic Account Manager-Workflows, Mid-Atlantic

Marketing

Product Manager-Lunatic
Product Manager-Automation

Product Development

Senior Electrical Engineer

Build something big with us!

Send Resume

Board

READ BIO

Tim Harkness

Founder and CEO, Unchained Labs

Tim Harkness, Founder and CEO, Unchained Labs

Building great teams and great life sciences companies is just in Tim’s DNA. He has 2 successful exits under his belt and brings 20+ years of life science leadership experience to the Unchained Labs table. As CEO of ProteinSimple, Tim and team built a unique protein analysis pure-play from scratch and sold it for $300M. Prior to that he helped build Molecular Devices into a diversified life science tools provider and sold it for over $600M. In his early career as a healthcare investment banker, Tim helped raise over $1B for life science companies in the public equity markets. He currently sits on the Board of Directors at Data Sciences International, a private life science technology company and at ALDA, the Life Sciences and Diagnostic Tools Association. He is a Founding Venture Partner at Tri-Valley Ventures, has an M.B.A. from Stanford and a B.B.A from the University of Wisconsin. Tim is married with 3 children, is out hacking around on the links or riding his bike whenever he can, and happily gets up at the crack of dawn to coach his son’s hockey and lacrosse teams.

READ BIO

Brent Ahrens

General Partner, TMIVCITW, Caanan Partners

Brent Ahrens, General Partner, TMIVCITW, Caanan Partners

His term sheets make the NY Times best seller list. His patents file themselves. Other venture capital-ists go through his trash can looking for business plans. He is…The Most Interesting Venture Capitalist in the World.

Brent Ahrens joined Canaan in 1999 as a member of the Kauffman Fellows Program. A raconteur ex-traordinaire, in his work hours, Brent focuses on healthcare investments and has led investments in life sciences companies such as DexCom (DXCM), Revivant (acquired by ZOLL), Peninsula Pharmaceuti-cals (acquired by JNJ), Cerexa (acquired by FRX), Calixa (acquired by CBST), Durata Therapeutics (DRTX), and Elevation Pharmaceuticals (acquired by DNPUF).

Brent serves on the board of Durata Therapeutics, a biopharmaceutical company pursuing late-stage clinical development of novel antibiotic programs. He is also on the boards of EndoGastric Solutions, the leading company offering medical devices for treatment of reflux disease; Minimally Invasive De-vices, a developer of a franchise of products that substantially improve visualization during laparoscop-ic surgery; Relievant MedSystems, a maker of minimally invasive devices to relieve chronic back pain; Semnur, a developer of pain managements solutions; and Spinifex, a biotech company developing new treatments for chronic pain.

Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Inno-vations, Ethicon Endo-Surgery (J&J), and IAP Research. He also has several surgical instrument patents to his credit.

Brent earned an MBA from the Tuck School of Business at Dartmouth College after graduating with a B.S. and M.S. in Mechanical Engineering from the University of Dayton.

READ BIO

Scott Beardsley

Senior Partner, Novo Ventures

Scott Beardsley, Senior Partner, Novo Ventures

Scott is employed as a Senior Partner at Novo Ventures (US), Inc., which provides financial investment consultancy services to Novo A/S. Prior to joining the Novo Ventures team in 2012, Scott was employed from 2009 through 2012 as a Senior Partner with Novo A/S’ Growth Equity team. Before joining Novo, Scott was an investment banker for 20 years in various capacities. Most recently, Scott was a Managing Director at JP Morgan in San Francisco, where he led the firm’s West Coast biopharmaceuticals effort. Before that, Scott led Piper Jaffray’s US biopharmaceuticals investment banking practice, was a banker in the Health Care Group at Montgomery Securities and a junior banker at Kidder, Peabody. Scott currently is a member of the board of directors of Inogen and served on the board of directors of Aerocrine AB, both publicly-traded medical technology companies. Scott received his Masters of Business Administration from the Anderson Graduate School of Management at UCLA and his Bachelors of Science in Business Administration from Colorado State University.

READ BIO

Heather Preston, MD

Partner and Managing Director, TPG Biotech

Heather Preston, MD, Partner and Managing Director, TPG Biotech

Prior to joining TPG Biotech in May 2005, Dr. Preston spent two years at JP Morgan Partners where she focused on medical device and biotechnology venture capital investing. Prior to JP Morgan Partners, Dr. Preston was an Entrepreneur-in-Residence with New Enterprise Associates. She also spent five years at McKinsey & Co. in New York, where she was a leader of their pharmaceutical and medical products consulting practice. She advised large pharmaceutical companies and biotechnology compa-nies on critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new technology acquisitions, new product launches and product growth strategies. Dr. Preston has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. Dr. Preston completed a post-doctoral fellowship in molecular biology at the Dana Farber Can-cer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospi-tal and subspecialized in Gastroenterology and Hepatology at UCSF. During her academic medical ca-reer, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Har-lech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award.

Dr. Preston co-founded Virobay Inc., a biotechnology company which is seeking to develop new ther-apies for the treatment of pain and auto-immune diseases. Dr. Preston currently serves on the board of directors of Albireo, Inc.; Alder BioPharmaceuticals, Inc. [ALDR]; Otonomy, Inc. [OTIC]; and Virobay, Inc. She previously served on the boards of Aptalis Pharma (acquired by Forest Labs in February 2014), Conventus, Vibrynt, VLST and Elevation Pharmaceuticals (acquired by Sunovion in September 2012) and is responsible for overseeing TPG Biotech’s investment in Par Pharmaceuticals.

READ BIO

Max Carnecchia

CEO, Illuminate Education

Max Carnecchia, CEO, Illuminate Education

Max Carnecchia is the Chief Executive Officer of Illuminate Education, which creates cloud delivered tools for educators that promote student success. Over 7 million K-12 students benefit from the Illuminate Education solutions. Illuminate Education is an Insight Venture Partners portfolio company.

Before joining Illuminate Education, Max was the Chief Executive Officer of BIOVIA-Dassault Systèmes. After acquiring Accelrys in 2014, Dassault Systèmes announced the creation of the BIOVIA brand combining Dassault Systèmes’ own efforts in BioIntelligence, their collaborative 3D EXPERIENCE technologies and leading life sciences and materials science solutions from Accelrys. Prior to this, Mr. Carnecchia had served as President and CEO of Accelrys and as a member of the Board of Directors since 2009. Mr. Carnecchia led Accelrys through significant growth and transformation, successfully transitioning the company to the leading global provider of Scientific Product Lifecycle Management software and services.

Prior to Accelrys, Mr. Carnecchia served as President of Interwoven, a global leader in content management solutions, having previously served as Vice President of Alliances and Senior Vice President of Worldwide Field Operations after joining Interwoven in 2001. Prior to this, Mr. Carnecchia served as Vice President of Global Sales for Xoriant; Vice President of Worldwide Field Operations for Smart DB Corporation sales; and he held management positions at Intel and Group 1 Software.

Mr. Carnecchia holds a Bachelor of Engineering in Electrical Engineering from The Stevens Institute of Technology. He served on the Board of Directors of Guidance Software (NASDAQ: GUID), which develops and provides software solutions for cyber security. He also served on the Board of Directors of ALDA (Analytical Life Science & Diagnostics Association), an industry trade association for companies that develop and supply life science, analytical and diagnostics products and services.